Tremelimumab (CP-675,206): A fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers

Expert Opinion on Biological Therapy

Volumn 8, Issue 10, 2008, Pages 1583-1593

  Tarhini, Ahmad A ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Cancer immunotherapy; CP 675,206; Cytotoxic T lymphocyte associated antigen 4; Monoclonal antibody; Tremelimumab

Indexed keywords

ALPHA2B INTERFERON; CPG 7909; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GEMCITABINE; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A{26-35}; PLATINUM COMPLEX; SUNITINIB; TICILIMUMAB; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADRENAL DISEASE; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLITIS; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DIARRHEA; DIVERTICULAR PERFORATION; DIVERTICULITIS; DOSAGE SCHEDULE COMPARISON; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOPHYSIS DISEASE; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PERFORATION; PRURITUS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SUDDEN DEATH; T LYMPHOCYTE ACTIVATION; THYROID DISEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 54349094280     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.10.1583     Document Type: Article

References (57)

1. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997;80:1198-220
2. Tarhini AA, Agarwala SS. Cutaneous melanoma: available therapy for metastatic disease. Dermatol Ther 2006;19:19-25
3. Rosenberg SA. Principles of cancer management: biologic therapy. In: De Vita VT, Hellman S, Rosenberg SA, editors, Cancer principles and practice of oncology. 7th edition. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 307-33
4. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80
5. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resecred cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17
6. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105-16
7. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/ S9111/C9190. J Clin Oncol 2000;18:2444-58
8. Garcia JA, Rini BI. Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 2007;57:112-25
9. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998;338:1272-8
10. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96
11. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Ann Rev Immunol 1996;14:233-58
12. Linsley PS, Brady W, Urnes M, et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-9
13. Thompson CB, Allison JP. The emerging role of CTLA-4 as an immune attenuator. Immunity 1997;7:445-50
14. McCoy KD, Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol Cell Biol 1999;77:1-10
15. Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 1995;3:541-7
16. Alegre M-L, Shiels H, Thompson CB, et al. Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 1998;161:3347-56
17. Krummel MF, Allison JP, CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995;182:459-65
18. Kwon ED, Hurwitz AA, Foster BA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA;94:8099-103
19. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-6
20. Kwon ED, Foster BA, Hurwitz AA, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci USA 1999;96:15074-9
21. Canniff PC, Donovan CB, Burkwit JJ, et al. CP-675,205 anti-CTLA4 antibody clinical candidate enhances IL-2 production in cancer patient T cells in vitro regardless of tumor type or stage of disease [abstract 709]. Poster presented at: 95th Annual Meeting of the American Association for Cancer Research; 27-31 March 2004; Orlando, FL, USA
22. Hanson DC, Canniff PC, Primiano MJ, et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206 [abstract 3802]. Poster presented at: 95th Annual Meeting of the American Association for Cancer Research; 27-31 March 2004; Orlando, FL, USA
23. Jakobovits A, Amado RG, Yang X, et al. From XenoMouse technology to panitumumab, the first fully human antibody product from transgenic mice. Nat Biotechnol 2007;25:1134-43
24. Steinmeyer DE, McCormick EL. The art of antibody process development. Drug Discov Today 2008;13:613-8
25. Finch G, Hanson D, Wang F, et al. Toxicology studies to support clinical development of tremelimumab, a cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blocking monoclonal antibody [abstract 2322]. Poster presented at: the Society of Toxicology Annual Meeting; 16-20 March 2008; Seattle, WA, USA
26. Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte-associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 2007;12:873-83
27. Ribas A, Camacho LH, Lopez-Berestein G, et al. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 2005;23:8968-77
28. Camacho LH, Ribas A, Glaspy JA, et al. Phase 1 clinical trial of anti-CTLA4 human monoclonal antibody CP-675,206 in patients (pts) with advanced solid malignancies [oral presentation] [abstract 2505]. Presented at: 40th Annual Meeting of the American Society of Clinical Oncology (ASCO); 5-8 June 2004; New Orleans, LA, USA
29. Morell A, Terry WD, Waldmann TA. Metabolic properties of IgG subclasses in man. J Clin Invest 1970;49:673-80
30. Ribas A, Bozon VA, Lopez-Berestein G, et al. Phase 1 trial of monthly doses of the human anti-CTLA4 monoclonal antibody CP-675,206 in patients with advanced melanoma [abstract 7524]. J Clin Oncol 2005;23(Suppl):716s
31. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004;93:2645-68
32. Ribas A, Antonia S, Sosman J, et al. Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma [oral presentation] [abstract 3000]. Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO); 1-5 June 2007; Chicago, IL, USA
33. Chung KY, Gore I, Fong L, et al. A phase II study of tremelimumab (CP-675,206), an anti-CTLA4 monoclonal antibody, in patients with refractory metastatic colorectal cancer [oral presentation]. Presented at: International Society for Biological Therapy of Cancer (iSBTc) 22nd Annual Meeting; 2-4 November 2007; Boston, MA, USA
34. US National Institutes of Health. Phase 2 randomized study of CP-675,206 or best supportive care immediately after platinum-based therapy for non-small cell lung cancer (NSCLC). Available from: http://www.clinicaltrials.gov [Accessed 25 June 2008]
35. US National Institutes of Health. Dose-finding study of CP-675,206 and SU011248 in patients with metastatic renal cell carcinoma. Available from: http://www.clinicaltrials.gov [Accessed 25 June 2008]
36. US National Institutes of Health. CP-675,206 with neoadjuvant hormone therapy in patients with high risk prostate cancer. Available from: http://www.clinicaltrials.gov [Last accessed 25 June 2008]
37. Wallis N, Bulanhagui C, Dorazio PC, et al. Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer [abstract 3040]. Poster presented at: 44th Annual Meeting of the American Society of Clinical Oncology (ASCO); 30 May - 3 June 2008; Chicago, IL, USA
38. Gomez-Navarro J, Sharma A, Bozon V, et al. Dose and schedule selection for the anti-CTLA4 monoclonal antibody ticilimumab in patients (pts) with metastatic melanoma [abstract 8032]. J Clin Oncol 2006;24(Suppl):460s
39. Kirkwood JM, Lorigan P, Hersey P, et al. A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma [poster and discussion] [abstract 9023]. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology (ASCO); 30 May - 3 June 2008; Chicago, IL, USA
40. Chung KY, Dorazio P, Pavlov D, et al. Survival of patients with refractory metastatic colorectal cancer treated with tremelimumab (CP-675,206), an anti-CTLA4 monoclonal antibody in a phase II study [abstract 351]. Poster presented at the 2008 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology; 25-27 January 2008; Orlando, FL, USA
41. Tarhini AA, Moschos SS, Schlesselman JJ, et al. Phase II trial of combination biotherapy of high-dose interferon alfa-2b and tremelimumab for recurrent inoperable stage III or stage IV melanoma [oral presentation] [abstract 9009]. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology (ASCO); 30 May - 3 June 2008; Chicago, IL, USA
42. Ribas A, Comin-Anduix B, Jalil J, et al. Combination of dendritic cell (DC) vaccination with CTLA4 blockade in patients (pts) with metastatic melanoma: a phase 1 clinical trial [oral presentation] [abstract 2537]. Presented at the American Association for Cancer Research (AACR) Annual Meeting; 12-16 April 2008; San Diego, CA, USA
43. Ribas A, Hauschild A, Kefford R, et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [oral presentation] [abstract LBA9011]. Presented at: 44th Annual Meeting of the American Society of Clinical Oncology (ASCO); 30 May-3 June 2008; Chicago, IL, USA
44. Ralph C, Elkord E, Thistlethwaite FC, et al. A phase II study of CP-675,206 in advanced gastric and esophageal adenocarcinoma: clinical and immunological results [oral presentation] [abstract 2835]. Presented at the American Association for Cancer Research (AACR) Annual Meeting; 12-16 April 2008; San Diego, CA, USA
45. Noe DA, Sharma A. Potential determinants of clinical efficacy of ticilimumab in melanoma [oral presentation] [abstract C30]. Presented at: AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 14-18 November 2005; Philadelphia, PA, USA
46. Gomez-Navarro J, Antonia S, Sosman J, et al. Survival of patients (pts) with metastatic melanoma treated with the anti-CTLA4 monoclonal antibody (mAb) CP-675,206 in a phase I/II study [abstract 8524]. Poster presented at: 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO); 1-5 June 2007; Chicago, IL, USA
47. Korn EL, Liu P-Y, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008;26:527-34
48. Chung KY, Gore I, Fong L, et al. A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic colorectal cancer [abstract 3035]. Poster presented at: 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO); 1-5 June 2007; Chicago, IL, USA
49. US National Institutes of Health. A phase 1 study testing CP-675,206 + gemcitabine in patients with previously treated, advanced pancreatic cancer. Available from: http://www.clinicaltrials.gov [Last accessed 25 June 2008]
50. Antonia S, Sosman J, Kirkwood JM, et al. Natural history of diarrhea associated with the anti-CTLA4 monoclonal antibody CP-675,206 [poster] [abstract 3038]. J Clin Oncol 2007;25(Suppl):127s
51. Bulanhagui C, ElSawah G, Wallis N, et al. Frequency, severity, and timing of immune-related adverse events in patients with metastatic melanoma treated with tremelimumab (CP-675,206) [poster]. Presented at: the Fifth International Symposium on Melanoma and Other Cutaneous Malignancies; 7-8 March 2008; New York, NY, USA
52. Weber JS, Hersh EM, Yellin M, et al. The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma [poster] [abstract 8523]. J Clin Oncol 2007;25(Suppl):477s
53. Pavlov D, Bulanhagui C, Wallis N, et al. Immune-related adverse events in patients with melanoma treated with tremelimumab (CP-675,206) [oral presentation]. Presented at: International Society for Biological Therapy of Cancer 22nd Annual Meeting; 2-4 November 2007; Boston, MA, USA
54. Ghiringhelli F, Menard C, Mateus C, et al. Effect of CTLA-4 blockade on lymphocyte resistance to regulatory T cells in advanced melanoma and use as a surrogate marker of efficacy o f tremelimumab [abstract 3021]. J Clin Oncol 2008;26(Suppl):137s
55. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006;354:709-18
56. Phan GO,, Attia P, Steinberg SM, et al. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol 2001;19:3477-82
57. Yurkovetsky ZR, Kirkwood JM, Edington HD, et al. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-α2b. Clin Cancer Res 2007; 13:2422-8